Ipsen SA Announces Successful Completion of European Decentralised Registration Procedure for Eziclen/Izinova

Ipsen SA announced that Eziclen/Izinova (BLI-800) successfully completed its European decentralized registration procedure involving sixteen countries. The product will be indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel (e.g. bowel visualization including bowel endoscopy and radiology or surgical procedure). Izinova/Eziclen (BLI800) was developed in the United States by Braintree Laboratories Inc and has been approved by the FDA since 2010. In 2009, Ipsen acquired the exclusive manufacturing, marketing and distribution rights of Braintree’s formulation BLI-800. The agreement covers countries within the European Union, Commonwealth of Independent States, selected Asian countries (including China) and some North African countries.